About CRC

Founded in 2006, Cognitive Research Corporation (CRC) is a privately-held, full-service CRO that specializes in central nervous system (CNS) and early phase product development for pharmaceutical, nutraceutical, biotechnology, and medical device companies. With offices in Florida, and relationships with experienced research facilities around the country, CRC is well-positioned to conduct clinical studies at any stage.

CRC provides services that are comprehensive, flexible, quality-driven and cost-effective. CRC’s focus is on providing a seamless extension of your organization, allowing you to reach your goals in a timely, efficient manner.

In addition to CRO services, CRC has developed proprietary technologies, including sophisticated neuropsychological assessment and state-of-the-art simulation technologies which they apply in a broad range of studies.

Download the CRC fact sheet.

Download a presentation about CRC’s capabilities.

CRC’s Relationship with Clinical Trial Centers Alliance

In many instances, sponsors request a streamlined solution to meet CRO + site deliverables under one contract. Based on our longstanding relationship with the founders of CRC, we’ve successfully collaborated to conduct healthy and patient population studies as an integrated team. Our partnership is by no means exclusive, as we continue to work with all CROs, but we are able to offer a bundled option when advantageous to sponsors. As with our Alliance research sites, CRC is an independent entity – not part of an SMO or financially linked with our sites.

CRO Services

CRC’s team brings broad, deep expertise in clinical trial design and execution, data management, biostatistics, medical writing, regulatory affairs, quality assurance, and media services. CRC has unique depth of expertise in CNS populations as well as healthy subject protocols. Their executive and clinical staff have decades of experience supporting successful clinical programs. With a nimble size and hands-on executive management, you will always get the “A” team – there is no other team at CRC.

Proprietary Psychometric Technologies

CRC Driving Simulator (CRCDS)
CRC is the exclusive provider of the state-of-the-art PC-based driving simulator, the CRCDS MiniSim, developed in partnership with the University of Iowa. The CRCDS is used to evaluate the effects of age, trauma, neurologic disease, alcohol, fatigue, and a wide variety of drugs on driving performance in both normal and patient populations. The CRCDS MiniSim has been fully validated for use in clinical trials. CRC has a fleet of identical driving simulators capable of conducting single or multi-site registration trials in the U.S., Canada, and Europe.

Download the CRCDS fact sheet.

CogScreen® is a standardized, validated computer-administered and scored neuropsychological test battery developed by Dr. Gary Kay and his colleagues. The battery was designed to rapidly assess deficits or changes in attention, immediate and working memory, visual perceptual functions, sequencing functions, logical problem solving, calculation skills, reaction time, simultaneous information processing abilities, and executive functions. In neuropsychological research CogScreen® has proven to be a highly sensitive test to the presence of mild brain dysfunction secondary to injury or disease and to changes in brain functioning caused by various medications, sleep deprivation, allergen exposure, hypoxia, and normal aging. The outstanding reliability and validity of CogScreen® is well documented in both the comprehensive test manual and in numerous publications.

CRCDS Publications:

Human Psychopharmacology: Clinical and Experimental – April 22, 2017; Research Article Authored by Dr. Kay
Next-day residual effects of flibanserin on simulated driving performance in premenopausal women

Human Psychopharmacology: Clinical and Experimental – February 16, 2016; Research Article Authored by Dr. Kay
Next-day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in healthy volunteers: a phase 3, randomized, double-blind, placebo-controlled, crossover trial


For more information or to further discuss your study needs please contact:
Bobbie Theodore, M.S.
Alliance Director
(o) (916) 939-6696
(c) (916) 803-7149